Isan Chen
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research 12
- Renal cell carcinoma treatment 11
- Cancer Research top 0.2%
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research 8
- Cancer Immunotherapy and Biomarkers 6
- Cancer-related Molecular Pathways 6
- Molecular Biology top 1%
- Renal and related cancers 6
- Genetics top 2%
-
- Phagocytosis and Immune Regulation 6
-
- Radiopharmaceutical Chemistry and Applications 5
- Co-authors
- Sindy T. KimM. Dror MichaelsonRonald M. BukowskiThomas E. HutsonRobert J. MotzerRobert A. FiglinPiotr TomczakSylvie Négrier
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Isan Chen
39 papers receiving 8.9k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Pulmonary and Respiratory Medicine 7.0k
- Cancer Research 3.1k
- Oncology 3.6k
- Molecular Biology 4.8k
- Genetics 383
Countries citing papers authored by Isan Chen
This map shows the geographic impact of Isan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isan Chen more than expected).
Fields of papers citing papers by Isan Chen
This network shows the impact of papers produced by Isan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isan Chen. The network helps show where Isan Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Isan Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 2 | |
| 2 | 2019 | 1 | |
| 3 | 2017 | 3 | |
| 4 | 2017 | 3 | |
| 5 | 2015 | 3 | |
| 6 | A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509breakdown → | 2013 | 455 |
| 7 | 2013 | 204 | |
| 8 | 2012 | 15 | |
| 9 | 2012 | 10 | |
| 10 | 2012 | 75 | |
| 11 | 2010 | 22 | |
| 12 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinomabreakdown → | 2009 | 1711 |
| 13 | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitrobreakdown → | 2009 | 1044 |
| 14 | 2009 | 5 | |
| 15 | 2008 | 321 | |
| 16 | 2008 | 7 | |
| 17 | 2008 | 81 | |
| 18 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinomabreakdown → | 2007 | 4471 |
| 19 | 2007 | 1 | |
| 20 | 2006 | 30 |
About Isan Chen
Isan Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 41 papers that have together received 9.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (12 papers), Renal cell carcinoma treatment (11 papers), Pancreatic and Hepatic Oncology Research (8 papers), Renal and related cancers (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Phagocytosis and Immune Regulation (6 papers), Cancer-related Molecular Pathways (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.0k citations), Cancer Research (3.1k citations) and Oncology (3.6k citations). Isan Chen has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Sindy T. Kim, M. Dror Michaelson, Ronald M. Bukowski, Thomas E. Hutson, Robert J. Motzer, Robert A. Figlin, Piotr Tomczak, Sylvie Négrier, Cezary Szczylik and Stéphane Oudard. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Research, Clinical Genitourinary Cancer and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.